Melodiol Global Health Limited has delivered $1.6 million in new revenue and confirmed POs during Third Quarter CY2023, which has laid a solid foundation for the Company to continue its current growth trajectory. The strong start to the September quarter follows record revenue during Second Quarter CY2023 of $4.74 million, which marked a 105% increase on First Quarter CY2023. New sales during Third Quarter CY2023 takes total unaudited revenue to date for the year to AUD 8.6 million - approximately equal to record breaking revenues of AUD 8.7 million for the entire of CY2022.

Third Quarter CY2023 revenue has been primarily underpinned by Melodiol's two 100%-owned subsidiaries, specialist medicinal cannabis distributor Health House International (`HHI') and Mernova Medicinal Inc. (`Mernova'), a leading supplier of recreational cannabis products in the Canadian market, as well as strong contributions from Creso Pharma Switzerland.